GamaMabs Pharma S.A.

https://www.gamamabs.com

GamaMabs Pharma is a French Biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K, currently in advanced pre-clinical stage, which targets Anti-Mullerian Human Receptor 2 (AMHRII/MISIIR) in ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. The company develops low-fucose antibodies with increased activity through the activation of immune system cells. *

	Start	2013-06-01 established
	Industry	antibody cancer drug
	Industry 2	GM102 (3C23K anti-AMHRII/MISIIR antibody, GamaMabs)
	Person	Degove, Stéphane (Atamyo Therapeutics 2020– CEO + Co-Founder before GamaMabs Pharma + Endotis Pharma + Sanofi)
	Person 2	Prost, Jean-François (GamaMabs 201411 VP RnD + Strategy)

	Region	Toulouse
	Country	France
	Street	1 place Pierre Potier Centre Pierre Potier, Oncopole entrée B
	City	31106 Toulouse Cedex 1
	Tel	+33-5-3161-6069
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for GamaMabs Pharma S.A.

[1] GamaMabs Pharma S.A.. (9/17/18). "Press Release: GamaMabs Pharma Starts a Phase 2 Study of Monoclonal Antibody GM102 in Patients with Advanced or Metastatic Colorectal Cancer". Paris & Toulouse....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)